What is the recommended tapering schedule to switch from alprazolam (Xanax) 1 mg daily as needed to clonazepam (Klonopin) 0.5 mg daily as needed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Alprazolam 1mg to Clonazepam 0.5mg Daily PRN

Direct substitution of clonazepam 0.5mg for alprazolam 1mg is appropriate as these are approximately equivalent doses, but the transition should be done gradually over 1-2 weeks to minimize withdrawal symptoms, decreasing alprazolam by 0.25mg every 3-7 days while simultaneously introducing clonazepam.

Rationale for the Switch

This transition makes clinical sense because:

  • Clonazepam has a longer half-life (30-40 hours vs. 11-15 hours for alprazolam), which reduces interdose anxiety and withdrawal symptoms 1
  • The dose equivalency is roughly 1:2 (0.5mg clonazepam ≈ 1mg alprazolam), so your proposed doses are appropriate
  • Research demonstrates 82% of patients rated clonazepam "better" after switching from alprazolam due to decreased dosing frequency and elimination of interdose anxiety 1

Recommended Tapering Schedule

Week 1:

  • Days 1-3: Alprazolam 0.75mg + Clonazepam 0.25mg daily
  • Days 4-7: Alprazolam 0.5mg + Clonazepam 0.25mg daily

Week 2:

  • Days 8-10: Alprazolam 0.25mg + Clonazepam 0.5mg daily
  • Days 11-14: Clonazepam 0.5mg daily only

This approach follows FDA guidance that alprazolam should be decreased by no more than 0.5mg every 3 days, though some patients require slower reduction 2. The gradual cross-taper minimizes the risk of withdrawal reactions, which can be life-threatening with abrupt benzodiazepine discontinuation 2.

Critical Considerations

Withdrawal symptoms to monitor:

  • Anxiety, tremor, sweating, tachycardia (common, mild) 3
  • Confusion, heightened sensory perception, paresthesias, muscle cramps (indicative of withdrawal syndrome) 4
  • Seizures (rare but serious with abrupt discontinuation)

If withdrawal symptoms emerge:

  • Pause the taper at the current dose level 5
  • Consider slowing the reduction to 0.25mg alprazolam every 7 days 6
  • Some patients may need even more gradual tapers over several weeks 7

Important Caveats

PRN dosing complicates this transition. If the patient is truly using alprazolam only "as needed" (not daily), the approach differs:

  • If usage is sporadic (2-3 times weekly), direct substitution of clonazepam 0.5mg for alprazolam 1mg on an as-needed basis is reasonable
  • If usage has become daily despite "PRN" labeling, treat as daily use and follow the taper schedule above
  • Daily use for >1 month constitutes physical dependence and requires gradual tapering 6

The EMPOWER trial demonstrated that gradual reduction over many weeks is essential for success, with 27% achieving discontinuation versus 5% in controls when proper tapering was employed 7. Research specifically on alprazolam-to-clonazepam switches confirms this medication change can be accomplished safely with appropriate dose equivalency and gradual transition 1, 8.

Avoid alternate-day dosing during this taper, as this creates pronounced receptor occupancy variation and increases withdrawal risk 9.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.